Consensus recommendations for the diagnosis, treatment and control of Mycobacterium ulcerans infection (Bairnsdale or Buruli ulcer) in Victoria, Australia

Paul D R Johnson, John A Hayman, Tricia Y Quek, Janet A M Fyfe, Grant A Jenkin, John A Buntine, Eugene Athan, Mike Birrell, Justin Graham and Caroline J Lavender, on behalf of the Mycobacterium ulcerans Study Team*
Med J Aust 2007; 186 (2): 64-68.
  • Paul D R Johnson1
  • John A Hayman2
  • Tricia Y Quek3,4
  • Janet A M Fyfe5
  • Grant A Jenkin6
  • John A Buntine7
  • Eugene Athan3,4
  • Mike Birrell8
  • Justin Graham6
  • Caroline J Lavender5
  • on behalf of the Mycobacterium ulcerans Study Team*

  • 1 Department of Infectious Diseases, Austin Health, Melbourne, VIC.
  • 2 Department of Anatomy and Cell Biology, Monash University, Melbourne, VIC.
  • 3 Department of Clinical and Biomedical Sciences, University of Melbourne, Melbourne, VIC.
  • 4 Department of Infectious Diseases, Barwon Health, Geelong, VIC.
  • 5 Victorian Infectious Diseases Reference Laboratory, Melbourne, VIC.
  • 6 Southern Health, Melbourne, VIC.
  • 7 Cornell Specialist Centre, Melbourne, VIC.
  • 8 Point Lonsdale Medical Group, Point Lonsdale, VIC.


We thank Mr Dallas Wilson for his expert assistance with audiovisuals and recording of the conference proceedings.

Competing interests:

None identified.

  • 1. World Health Organization. Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer). (accessed Jun 2006).
  • 2. MacCallum P, Tolhurst JC, Buckle G, Sissons HA. A new mycobacterial infection in man. J Pathol Bacteriol 1948; 60: 93-122.
  • 3. Johnson PDR, Stinear T, Small PLC, et al. Buruli ulcer (M. ulcerans infection): new insights, new hope for disease control. PLoS Med 2005; 2(4): e108.
  • 4. George KM, Chatterjee D, Gunawardana G, et al. Mycolactone: a polyketide toxin from Mycobacterium ulcerans required for virulence. Science 1999; 283: 854-857.
  • 5. Asiedu K, Etuaful SA. Socioeconomic implications of Buruli ulcer in Ghana: a three-year review. Am J Trop Med Hyg 1998; 59: 1015-1022.
  • 6. Drummond C, Butler JR. Mycobacterium ulcerans treatment costs, Australia. Emerg Infect Dis 2004; 10: 1038-1043.
  • 7. Johnson PDR, Veitch MGK, Leslie DE, et al. The emergence of Mycobacterium ulcerans infection near Melbourne. Med J Aust 1996; 164: 76-78.
  • 8. Jenkin GA, Smith M, Fairley M, Johnson PDR. Acute, oedematous Mycobacterium ulcerans infection in a farmer from far north Queensland. Med J Aust 2002; 176: 180-181. <MJA full text>
  • 9. Francis G, Whitby M, Woods M. Mycobacterium ulcerans infection: a rediscovered focus in the Capricorn Coast region of central Queensland [letter]. Med J Aust 2006; 185: 179-180. <MJA full text>
  • 10. Stinear TP, Jenkin GA, Johnson PD, Davies JK. Comparative genetic analysis of Mycobacterium ulcerans and Mycobacterium marinum reveals evidence of recent divergence. J Bacteriol 2000; 182: 6322-6330.
  • 11. Flood P, Street A, O’Brien P, Hayman J. Mycobacterium ulcerans infection on Phillip Island, Victoria. Med J Aust 1994; 160: 160.
  • 12. Johnson PD, Veitch MG, Flood PE, Hayman JA. Mycobacterium ulcerans infection on Phillip Island, Victoria. Med J Aust 1995; 162: 221-222.
  • 13. Tiong A. The epidemiology of a cluster of Mycobacterium ulcerans infections in Point Lonsdale. Victorian Infect Dis Bull 2005; 8: 2-4. (accessed Aug 2006).
  • 14. Ross BC, Marino L, Oppedisano F, et al. Development of a PCR assay for rapid diagnosis of Mycobacterium ulcerans infection. J Clin Microbiol 1997; 35: 1696-1700.
  • 15. Veitch MGK, Johnson PDR, Flood PE, et al. A large localized outbreak of Mycobacterium ulcerans infection on a temperate southern Australian island. Epidemiol Infect 1997; 119: 313-318.
  • 16. Atkinson RK, Farrell DJ, Leis AP. Evidence against the involvement of Mycobacterium ulcerans in most cases of necrotic arachnidism. Pathology 1995; 27: 53-57.
  • 17. Russell FM, Starr M, Hayman J, et al. Mycobacterium ulcerans infection diagnosed by polymerase chain reaction. J Paediatr Child Health 2002; 38: 311-313.
  • 18. Debacker M, Aguiar J, Steunou C, et al. Buruli ulcer recurrence, Benin. Emerg Infect Dis 2005; 11: 584-589.
  • 19. Etuaful S, Carbonnelle B, Grosset J, et al. Efficacy of the combination rifampin-streptomycin in preventing growth of Mycobacterium ulcerans in early lesions of Buruli ulcer in humans. Antimicrob Agents Chemother 2005; 49: 3182-3186.
  • 20. O’Brien DP, Hughes AJ, Cheng AC, et al. Outcomes for Mycobacterium ulcerans infection with combined surgery and antibiotic therapy: findings from a south-eastern Australian case series. Med J Aust 2007; 186: 58-68. <MJA full text>
  • 21. Krieg RE, Wolcott JH, Confer A. Treatment of Mycobacterium ulcerans infection by hyperbaric oxygenation. Aviat Space Environ Med 1975; 46: 1241-1245.
  • 22. Dega H, Bentoucha A, Robert J, et al. Bactericidal activity of rifampin-amikacin against Mycobacterium ulcerans in mice. Antimicrob Agents Chemother 2002; 46: 3193-3196.
  • 23. World Health Organization. Global Buruli ulcer initiative. (accessed Aug 2006).
  • 24. Bentoucha A, Robert J, Dega H, et al. Activities of new macrolides and fluoroquinolones against Mycobacterium ulcerans infection in mice. Antimicrob Agents Chemother 2001; 45: 3109-3112.
  • 25. Ji B, Lefrancois S, Robert J, et al. In vitro and in vivo activities of rifampin, streptomycin, amikacin, moxifloxacin, R207910, linezolid, and PA-824 against Mycobacterium ulcerans. Antimicrob Agents Chemother 2006; 50: 1921-1926.
  • 26. Yoshida K, Yabe K, Nishida S, et al. Pharmacokinetic disposition and arthropathic potential of oral ofloxacin in dogs. J Vet Pharmacol Ther 1998; 21: 128-132.
  • 27. Zimbabwe Bangladesh South Africa (Zimbasa) Dysentery Study Group. Multicenter, randomized, double blind clinical trial of short course versus standard course oral ciprofloxacin for Shigella dysenteriae type 1 dysentery in children. Pediatr Infect Dis J 2002; 21: 1136-1141.
  • 28. Ross BC, Johnson PDR, Oppedisano F, et al. Detection of Mycobacterium ulcerans in environmental samples during an outbreak of ulcerative disease. Appl Environ Microbiol 1997; 63: 4135-4138.
  • 29. Stinear TP, Davies JK, Jenkin GA, et al. Identification of Mycobacterium ulcerans in the environment from regions in southeast Australia in which it is endemic with sequence-capture PCR. Appl Environ Microbiol 2000; 66: 3206-3213.
  • 30. Marsollier L, Robert R, Aubry J, et al. Aquatic insects as a vector for Mycobacterium ulcerans. Appl Environ Microbiol 2002; 68: 4623-4628.
  • 31. Marston BJ, Diallo MO, Horsburgh CR Jr, et al. Emergence of Buruli ulcer disease in the Daloa region of Cote d’Ivoire. Am J Trop Med Hyg 1995; 52: 219-224.
  • 32. Aiga H, Amano T, Cairncross S, et al. Assessing water-related risk factors for Buruli ulcer: a case–control study in Ghana. Am J Trop Med Hyg 2004; 71: 387-392.
  • 33. Raghunathan PL, Whitney EA, Asamoa K, et al. Risk factors for Buruli ulcer disease (Mycobacterium ulcerans infection): results from a case–control study in Ghana. Clin Infect Dis 2005; 40: 1445-1453.
  • 34. Victorian Department of Human Services. Notifications of infectious diseases: summary reports. (accessed Aug 2006).


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Responses are now closed for this article.